Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Neurology Neuroimmunology & Neuroinflammation Année : 2021

Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study

Résumé

Objective To compare the humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with multiple sclerosis (MS) receiving different disease-modifying treatments (DMTs). Methods Patients with MS with coronavirus disease 2019 (COVID-19) and available anti–SARS-CoV-2 serology were included. The primary endpoint was the anti–SARS-CoV-2 immunoglobulin G (IgG) index. The multivariate analysis was adjusted for COVID-19 severity, SARS-CoV-2 PCR result, and the time between COVID-19 onset and the serology. Results We included 61 patients with available IgG index. The IgG index was lower in patients with fingolimod or anti-CD20 monoclonal antibodies compared with patients without treatment (p < 0.01), patients with interferon β-1a or glatiramer (p < 0.01), and patients with another DMT (p = 0.01). The IgG index was correlated with the time between COVID-19 onset and serology (r = −0.296 [−0.510; −0.0477], p = 0.02). Conclusions Humoral response after COVID-19 was lower in patients with MS with fingolimod or anti-CD20 mAb. These patients could therefore be at risk of recurrent infection and could benefit from anti–SARS-CoV-2 vaccination. The humoral response after vaccination and the delay before vaccination need to be evaluated. Classification of Evidence This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs.

Dates et versions

hal-03603577 , version 1 (09-03-2022)

Identifiants

Citer

Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, Livia Lanotte, Marie-Céline Fleury-Lesaunier, et al.. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study. Neurology Neuroimmunology & Neuroinflammation, 2021, 8 (5), pp.e1055. ⟨10.1212/nxi.0000000000001055⟩. ⟨hal-03603577⟩

Collections

INSERM SITE-ALSACE
21 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More